Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $47.00 price target on the stock. Separately, Piper Sandler reiterated an overweight rating and issued a $8.00 price objective on shares of Tempest Therapeutics […]
More Stories
Who is Allie Rebelo? And Her Relationship With Justin and Hailey Bieber
Have you also seen Allie Rebelo video on TikTok? And now wants to know about who is Allie Bieber and...
Trump Tells Germany’s Merz to Stop Interfering Over Iran
By Victoria Friedman U.S. President Donald Trump has again criticized German Chancellor Friedrich Merz over Iran, telling Merz to stop...
Trump Signs Order Targeting ‘Bloated Overhead’ in Federal Contracts
By Tom Gantert President Donald Trump signed an executive order Thursday that seeks to address longstanding problems in the federal...
Trump Signs DHS Funding Bill, Ending Shutdown
By Jackson Richman and Joseph Lord President Donald Trump on April 30 signed legislation ending the Department of Homeland Security...
US Economy Rebounds With 2 Percent Growth in 1st Quarter
By Andrew Moran The U.S. economy registered a solid rebound in the first quarter after a disappointing end to 2025,...
Louisiana Governor Signals House Primaries Will Be Postponed After Supreme Court Redistricting Ruling
By Jacki Thrapp Louisiana plans to postpone U.S. House primaries in order to allow time for lawmakers to redraw and...